文献速递消化系统肿瘤支持与姑息治疗

严重毒性是否影响转移性结直肠癌患者接受姑息性全身治疗期间的总体生活质量?一项系统综述

Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review.
PubMed 文献 · Ann Oncol · 2017-01-01

该系统综述纳入2004至2016年发表的30项III期随机对照试验、共19863例转移性结直肠癌患者,评估严重毒性是否影响总体生活质量。结果显示25项试验(83%)治疗组间总体生活质量无差异,22项试验(73%)实验组毒性增加,其中19项(86%)总体生活质量未受影响或改善。作者认为总体生活质量用于比较治疗组不提供临床相关信息,亟需进一步考虑如何更好评估新药对患者生活质量的净效应。

要点

  • 30项III期随机对照试验中25项(83%)治疗组间总体生活质量无差异。
  • 22项试验(73%)实验组毒性较对照组增加,其中19项(86%)总体生活质量未受影响或改善。
  • 作者认为总体生活质量用于比较治疗组不提供临床相关信息,亟需进一步考虑如何更好评估新药对患者生活质量的净效应。

核心结论

  • III期随机对照试验中转移性结直肠癌患者的总体生活质量在治疗组间无差异,尽管实验组较标准治疗组毒性持续更高。
  • 基于这些发现,作者认为在转移性结直肠癌随机对照试验中使用总体生活质量比较治疗组不提供临床相关信息。
  • 作者指出亟需进一步考虑如何更好评估新药对患者生活质量的净效应。

研究设计与样本

  • 系统综述纳入2004至2016年发表的III期随机对照试验,评估转移性结直肠癌患者的姑息性全身治疗。
  • 共识别30项研究,纳入19863例患者。
  • 基于总体生活质量评分、治疗期间毒性(通过评分相关不良事件评估)和主要终点进行评价。

主要发现

  • 30项试验中25项(83%)未观察到治疗组间总体生活质量差异。
  • 30项试验中22项(73%)显示实验组较对照组治疗期间毒性增加。
  • 22项毒性更高的试验中19项(86%)总体生活质量结局未受影响或改善。
  • 11项主要终点更优的研究中10项未见总体生活质量改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New palliative systemic treatment regimens in patients with metastatic colorectal cancer (mCRC) have significantly improved overall survival and prognosis. These treatment regimens are often accompanied by increased toxicity, which may impair patients' quality of life (QOL). We systematically reviewed whether severe toxicity affects global QOL in patients with mCRC receiving palliative systemic treatment in recent published randomized controlled trials (RCTs). MATERIALS AND METHODS: Phase III RCTs evaluating palliative systemic treatments in patients with mCRC and published between 2004 and 2016 were considered. Studies were evaluated on the basis of global QOL scores, toxicity during treatment (assessed by scoring relevant adverse events) and primary outcomes (POs). RESULTS: A total of 30 studies were identified in which 19863 patients were included. In 25 out of these 30 trials (83%), no difference in global QOL between treatment arms was observed. In contrast, 22 out of 30 trials (73%) showed increased toxicity during treatment in the experimental arm as compared with the control arm. In 19 out of 22 trials with higher toxicity (86%) global QOL outcomes remained unaffected or improved. In ten out of eleven studies with a better PO, no improvement in global QOL was seen. CONCLUSION: Global QOL of patients with mCRC included in phase III RCTs evaluating palliative systemic treatment did not differ across treatment arms despite consistently higher toxicity during treatment of the experimental compared with the standard treatment arms. Based on these findings we conclude that the use of global QOL for comparing treatment arms in RCTs for patients with mCRC does not provide information of clinical relevance. Further consideration of how to better assess the net effect of new agents on patients' QOL is urgently needed.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Schuurhuizen CSEW, Braamse AMJ, Konings IRHM, et al. Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review. Ann Oncol. 2017. PMID: 27998965. doi:10.1093/annonc/mdw617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。